Sign in
4

Changes in Ownership

Relay Therapeutics, Inc. Filed Acc 0000950170-25-011327

Chief Financial Officer sold 58,936 shares at an average $4.55 ($268,339)

  • Chief Financial Officer acquired 139,141 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Catinazzo Thomas · Chief Financial Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2025-01-28 Sale : show line 1 in the form 10b5-1 −33,753 $4.63 $156,276 265,473 D
2025-01-28 Sale : show line 2 in the form 10b5-1 −2,283 $4.63 $10,570 263,190 D
2025-01-28 Grant or award : show line 3 in the form 10b5-1 +139,141 402,331 D
2025-01-29 Sale : show line 4 in the form 10b5-1 −2,109 $4.55 $9,596 400,222 D
2025-01-30 Sale : show line 5 in the form 10b5-1 −20,791 $4.42 $91,896 379,431 D
Open-market sales · 58,936 sh · avg $4.55 · $268,339
Loading xslF345X05/ownership.xml…